Evolv’s 34% Q2 growth and improving cash generation support a compelling transition story, but the $6.02 stock already discounts substantial execution and profitability improvement.
Evolv Technologies Holdings Inc is a pioneer in the physical security sector, specializing in the development, manufacture, and deployment of artificial intelligence-powered weapons screening systems [cite: 1, 2]. The company operates primarily within the hardware-enabled software-as-a-service market, offering an alternative to legacy security checkpoints [cite: 1, 2]. Unlike traditional walkthrough metal detectors that require slow, invasive, and single-file screening processes, this platform allows high-volume crowds to pass through entry portals at a natural walking pace without removing personal items from pockets or bags [cite: 3, 4]. Evolv organizes its operations around core urban high-throughput segments, focusing heavily on K-12 education, healthcare facilities, sports stadiums, performing arts venues, convention centers, and major industrial workplaces [cite: 2, 5].
The company's commercial engine functions through a dual-channel revenue model designed to maximize customer lifetime value and upfront cash generation [cite: 1, 6]. Under its pure-subscription model, marketed under a Security-as-a-Service framework, Evolv provides customers with its physical screening gateways, software access, maintenance, and data telemetry in exchange for a recurring multi-year fee, retaining ownership of the underlying hardware [cite: 1, 2]. Conversely, the purchase-subscription model utilizes channel partners and distributors to sell the physical portals directly to the customer upfront [cite: 1, 6]. This immediate transaction generates significant upfront product revenue, which is paired with a mandatory multi-year recurring software subscription to maintain active AI threat-detection capabilities on the physical units [cite: 1, 6].
Geographically, Evolv is concentrated in the North American market, with the United States representing its primary commercial and operating base [cite: 5, 7]. The company's customer base is diversified across public and private sectors, with public school systems representing approximately half of its total business footprint [cite: 5]. Evolv’s core offerings consist of its walkthrough gateway system, an autonomous bag-scanner, a perimeter-focused visual detection software layer, and a cloud-based analytics portal [cite: 3, 8, 9, 10, 11].
The primary driver of customer adoption over legacy alternatives is a fundamental improvement in checkpoint efficiency and operational economics [cite: 4]. Traditional metal detectors create massive bottlenecks, requiring visitors to divest physical items, step through portals individually, and submit to manual pat-downs or secondary wanding [cite: 4, 8]. Evolv's walkthrough portals process up to 4,000 individuals per hour for a dual-lane setup, which is more than ten times faster than traditional methods [cite: 3, 4]. This increased throughput allows venue operators to reduce security checkpoint labor costs by up to 70% while reclaiming physical lobby space for operations or revenue-generating activities [cite: 4, 5].
Evolv's operational model focuses on transitioning from transactional hardware installations to recurring, high-margin software integrations that embed its technology deep within a customer's security infrastructure [cite: 1, 2, 12]. This land-and-expand commercial strategy aims to secure initial gateway deployments and then expand across entire school districts, healthcare networks, or commercial venue groups [cite: 1].
The Evolv Safer Experience System comprises several integrated layers designed to detect, deter, and coordinate responses to security threats [cite: 10]. Understanding these individual products is essential to evaluating Evolv's market position:
Evolv's competitive advantage is supported by high customer switching costs, regulatory barriers, and its distribution network:
According to Evolv’s internal market analyses, the addressable global market is estimated at approximately $20 billion annually [cite: 4]. This projection is based on nearly 700,000 potential physical points of ingress across target sectors, with an average target contract value of $30,000 per threshold per year [cite: 4]. With Evolv’s current active footprint representing a small fraction of these target locations, the company has a long runway for organic expansion within its core verticals [cite: 3, 4].
Evolv competes in a bifurcated landscape consisting of legacy hardware manufacturers and emerging touchless AI screening startups [cite: 1, 16]:
Evolv maintains a leading market share in high-throughput urban screening venues [cite: 2, 17]. However, it faces competitive pressures in cost-sensitive segments like public schools, where competitors often underbid on simpler, hardware-only solutions [cite: 13, 18].
Evolv Technologies reported its financial results for the second quarter of fiscal 2026 ended June 30, 2026, on August 11, 2026 [cite: 6, 21]. The results show strong top-line momentum, narrowing GAAP losses, and a positive transition to operating cash flow generation [cite: 6, 22].
For Q2 2026, Evolv generated total revenue of $43.8 million, up 34% year-over-year compared to $32.5 million in Q2 2025 [cite: 6]. This top-line performance exceeded Wall Street consensus analyst expectations of $41.81 million by approximately 4.75% [cite: 15, 23]. GAAP gross profit rose to $22.0 million, representing a GAAP gross margin of 50.2%, compared to $16.2 million (49.8%) in the prior-year period [cite: 6].
On the bottom line, Evolv reported a GAAP net loss of $(9.3) million, or $(0.05) per basic and diluted share, showing improvement compared to a GAAP net loss of $(40.5) million, or $(0.25) per share, in Q2 2025 [cite: 6]. The narrowing of the GAAP net loss was supported by scaling gross margins, lower general and administrative expenses, and non-cash adjustments to the fair value of common stock and public warrant liabilities [cite: 6, 22]. Non-GAAP adjusted loss per share stood at $(0.02), beating the consensus analyst expectation of $(0.03) [cite: 6, 23].
For the first six months of fiscal 2026, total revenue reached $90.1 million, up 40% year-over-year from $64.6 million in the first half of 2025, driven by subscription growth and product shipments [cite: 22, 24].
| Financial Metric | Q2 2026 (Reported) | Q2 2025 (Prior Year) | Year-over-Year Change | Analyst Consensus | Performance vs. Consensus |
|---|---|---|---|---|---|
| Total Revenue | $43.8 million [cite: 6] | $32.5 million [cite: 6] | +34.0% [cite: 6] | $41.81 million [cite: 23] | Beat (+4.75%) [cite: 15] |
| GAAP Gross Margin | 50.2% [cite: 6] | 49.8% [cite: 6] | +0.4 percentage points [cite: 6] | N/A | N/A |
| GAAP Net Loss | $(9.3) million [cite: 6] | $(40.5) million [cite: 6] | Narrowed by 77.0% [cite: 6] | N/A | N/A |
| Adjusted EPS | $(0.02) [cite: 6] | $(0.03) [cite: 6] | Narrowed by 33.3% [cite: 6] | $(0.03) [cite: 23] | Beat (+$0.01) [cite: 23] |
| Adjusted EBITDA | $4.4 million [cite: 6] | $2.1 million [cite: 6] | +110.0% [cite: 6] | N/A | N/A |
| Ending ARR | $132.7 million [cite: 6] | $110.5 million [cite: 6] | +20.0% [cite: 6] | N/A | N/A |
Evolv is experiencing a rapid shift in its sales mix toward the purchase-subscription model [cite: 6]. Management raised its expectation for the purchase-subscription share of new deployments to 60% for full-year 2026, up from its previous estimate of 55% [cite: 6]. Under this model, hardware is sold upfront, generating immediate product revenue but requiring Evolv to recognize physical hardware manufacturing costs in the same quarter [cite: 6].
Product revenue surged by approximately 260% year-over-year to $9.1 million in Q2 2026 (from $2.5 million in Q2 2025) [cite: 6]. Consequently, GAAP gross margins for the first half of 2026 declined to 50.6% from 54.8% in H1 2025, as upfront hardware recognition pressured gross margin percentages despite driving absolute gross profit dollars [cite: 6, 24]. Subscription revenue remains the primary economic engine, increasing 23% year-over-year to $24.8 million in Q2 2026 [cite: 6].
Following the Q2 results, management raised its full-year fiscal 2026 guidance:
John Kedzierski, President and CEO, highlighted the onboarding of 70 new customers in Q2, the rapid expansion of eXpedite bag-scanners (with over 75 active eXpedite customers representing 6% of the base, up from 1% last year), and sequential improvements in contract renewals [cite: 6, 23, 27]. CFO Chris Kutsor emphasized that Evolv’s long-term financial framework targets a 25% revenue CAGR through 2031 [cite: 26], with adjusted EBITDA margins expanding annually, driving the company toward "Rule of 50" scale efficiency over time [cite: 26]. Additionally, management reiterated its goal to become free cash flow positive in the second half of 2026, supported by positive operating cash flow of $8.7 million in H1 2026 [cite: 22, 28].
As of June 30, 2026, Evolv's cash, cash equivalents, and marketable securities totaled $62.6 million [cite: 22] (with total cash, marketable securities, and restricted cash standing at $63.4 million [cite: 6, 24]). The company carries $30.0 million of term debt outstanding under its MidCap credit facilities, resulting in a net cash position of approximately $32.6 million [cite: 22, 29]. Total deferred revenue was $92.2 million, and Remaining Performance Obligations (RPO) sequentially expanded by $13.6 million to $312.6 million, highlighting multi-year visibility [cite: 21, 22]. Common stock shares outstanding increased to 180,839,400 as of June 30, 2026, due to stock option exercises and Restricted Stock Unit (RSU) vestings [cite: 22].
Trading at approximately $6.02 per share, Evolv carries a market capitalization of $1.12 billion [cite: 30]. Using the midpoint of raised FY 2026 revenue guidance ($182.5 million) [cite: 29], Evolv trades at an implied enterprise value to forward sales multiple of:
$\text{EV/Forward Sales} = \frac{\$1,120\text{M (Market Cap)} - \$32.6\text{M (Net Cash)}}{\$182.5\text{M (FY 2026 Revenue)}} \approx 5.96\text{x}$
This represents a discount to Evolv’s historical median Price-to-Sales multiple of 8.4x, reflecting market caution regarding path-to-profitability timing, and sits in line with security peers such as NAPCO Security Technologies (which carries an EV/Sales multiple of approximately 6.6x to 7.0x depending on fiscal cycles) [cite: 31, 32, 33].
Evaluating Evolv Technologies requires analyzing corporate governance history, product efficacy parameters, customer vertical concentration, and capitalization constraints.
Evolv is currently transitioning its primary hardware manufacturing and supply chain infrastructure to Plexus Corp [cite: 2, 34]. While management expects a full manufacturing ramp in the second half of 2026, any supply chain disruption, component shortage (such as elevated memory chip or sensor raw material costs), or manufacturing delay could severely constrain quarterly product delivery, halting the high-margin subscription attach rate [cite: 2, 34].
Additionally, in late 2024 and early 2025, Evolv was subjected to a severe internal accounting investigation regarding sales practices with its channel partners [cite: 35, 36]. The audit committee determined that transactions with a major distributor were subject to extra-contractual terms that prematurely recognized $4 million to $6 million in revenue, leading to the restatement of prior financial statements, terminations of several finance executives (including former CFO Mark Donohue), and delayed SEC filings [cite: 2, 36]. While new CFO Chris Kutsor has implemented systems to remediate these material weaknesses, lingering internal control deficiencies over financial reporting continue to pose operational risks [cite: 2, 37].
Evolv’s AI walkthrough screening is designed to balance threat detection with passenger flow [cite: 3]. However, the software is not foolproof [cite: 5]. In October 2022, an Evolv walkthrough scanner at a school in Utica, New York, failed to detect a seven-inch metallic knife that was subsequently used to stab a student [cite: 5]. This led the school district to increase system sensitivity settings, which subsequently triggered a 50% false-alarm rate, highlighting the delicate trade-off between throughput and comprehensive detection [cite: 5]. Further high-profile detection failures could permanently damage brand equity and trigger catastrophic liability claims, although DHS SAFETY Act protections mitigate certain terrorist-related litigation risks [cite: 14].
Approximately 50% of Evolv’s active business footprint is tied to K-12 public school districts [cite: 5]. Educational spending is highly dependent on federal, state, and local safety grants [cite: 8, 38]. Macroeconomic contractions or changes in political funding priorities for public education could restrict capital allocations for campus safety upgrades, severely slowing Evolv's sales cycle (which expanded from three months to five months in prior tightening cycles) [cite: 12].
In November 2024, the Federal Trade Commission (FTC) initiated a deceptive marketing complaint against Evolv, alleging the company made false and un-backed marketing claims regarding its scanners' ability to detect all metallic weapons, ignore harmless items, and reduce security labor costs [cite: 5, 39, 40]. Evolv resolved the FTC inquiry by agreeing to strict recordkeeping injunctions and offering a limited group of K-12 education customers (who signed contracts between April 2022 and June 2023) a 60-day window to cancel their multi-year contracts [cite: 5, 41]. Although no school customers exercised cancellation options during the initial period, the regulatory overhang prevents Evolv from making aggressive marketing claims, limiting its sales pitch relative to less-regulated startups [cite: 5, 41].
Furthermore, Evolv is currently managing a $15.0 million securities class-action settlement (scheduled for a final fairness hearing on September 24, 2026) and a series of derivative actions (hearing scheduled for October 21, 2026) [cite: 22, 42, 43]. While insurance is expected to cover a significant portion of these liabilities, any non-covered legal fees or expanded regulatory fines from ongoing SEC inquiries could drain liquid cash reserves [cite: 22, 42].
Extended periods of high interest rates increase the cost of debt, which can curtail commercial real estate development, hospital capital expansion projects, and discretionary municipal funding [cite: 7]. Because Evolv relies on new building construction and stadium retrofits for incremental growth, a macroeconomic slowdown directly shrinks its active pipeline [cite: 1, 2].
To help investors prioritize these various headwinds, Evolv’s operational threats are categorized across three strategic horizons:
To evaluate potential common-equity outcomes for Evolv Technologies over a five-year horizon (2026–2030), this report models High, Base, and Low operating scenarios [cite: 29]. This framework factors in the raised fiscal 2026 guidance, historical dilutive stock issuance, and valuation multiples supported by Evolv's SaaS-heavy platform [cite: 6, 22, 32].
Evolv successfully executes its Plexus contract manufacturing transition, stabilizing supply and supporting international expansion [cite: 2, 34]. The eXpedite bag scanner achieves a 15% attach rate across the installed base [cite: 27]. Subscription retention rates hold steady at 97%, and the company achieves positive cash self-funding in H2 2026 [cite: 28].
$EV_{2030} = \$445.56\text{M (Revenue)} \times 4.0\text{x Multiple} = \$1,782.24\text{M}$
$\text{Equity Value}_{2030} = \$1,782.24\text{M (EV)} + \$132.93\text{M (Net Cash)} = \$1,915.17\text{M}$
$\text{Implied Share Price}_{2030} = \frac{\$1,915.17\text{M (Equity Value)}}{199.61\text{M (Diluted Shares)}} \approx \mathbf{\$9.59\text{ USD}}$
This scenario yields a 59.3% total return from the current market price of $6.02, representing a 9.8% compound annual return [cite: 29, 30].
Evolv experiences rapid, widespread adoption of its adjacent eXpedite bag-screening system (reaching a 25% attach rate) and accelerates expansion into healthcare and corporate offices [cite: 8, 10]. Remediations of internal controls are completed smoothly, restoring institutional investor confidence and driving multiple expansion [cite: 2].
$EV_{2030} = \$528.38\text{M} \times 5.5\text{x Multiple} = \$2,906.09\text{M}$
$\text{Equity Value}_{2030} = \$2,906.09\text{M} + \$182.60\text{M} = \$3,088.69\text{M}$
$\text{Implied Share Price}_{2030} = \frac{\$3,088.69\text{M}}{194.74\text{M}} \approx \mathbf{\$15.86\text{ USD}}$
This scenario yields a 163.5% total return from the current market price of $6.02, representing a 21.4% compound annual return [cite: 30].
Evolv faces aggressive pricing pressure from competitors like CEIA OPENGATE and Xtract One, causing contract renewals to deteriorate [cite: 16, 18]. Funding constraints across K-12 school systems stall new orders [cite: 5, 8]. Lingering materials and labor costs prevent gross margins from scaling [cite: 6].
$EV_{2030} = \$283.23\text{M} \times 2.0\text{x Multiple} = \$566.46\text{M}$
$\text{Equity Value}_{2030} = \$566.46\text{M} + \$52.60\text{M} = \$619.06\text{M}$
$\text{Implied Share Price}_{2030} = \frac{\$619.06\text{M}}{211.56\text{M}} \approx \mathbf{\$2.93\text{ USD}}$
This scenario yields a negative 51.3% total return from the current market price of $6.02, representing a negative 13.5% compound annual return [cite: 30].
| Scenario | Revenue in Year 5 (USD) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $528.38M | 22.0% EBITDA | 5.5x EV/Sales | $6.02 [cite: 30] | $15.86 | 163.5% | 21.4% | 25.0% |
| Base Case | $445.56M [cite: 29] | 18.0% EBITDA [cite: 29] | 4.0x EV/Sales [cite: 29] | $6.02 [cite: 30] | $9.59 [cite: 29] | 59.3% [cite: 29] | 9.8% [cite: 29] | 50.0% |
| Low Case | $283.23M | 10.0% EBITDA | 2.0x EV/Sales | $6.02 [cite: 30] | $2.93 | -51.3% | -13.5% | 25.0% |
| Probability-Weighted | $425.68M | 17.0% EBITDA | 3.88x EV/Sales | $6.02 [cite: 30] | $9.49 | 57.6% | 9.5% | 100.0% |
ASYMMETRIC GROWTH PROFILE
To assess the present intrinsic value of Evolv Technologies Holdings Inc, this analysis conducts an unlevered Free Cash Flow to the Firm (FCFF) Discounted Cash Flow (DCF) model [cite: 29]. This intrinsic-value analysis is anchored to the exact operating views, revenue growth parameters, and dilution profiles outlined in the 5-Year Base Case scenario [cite: 29], extending these assumptions logically into a mature-stage terminal period.
The unlevered free cash flows are projected using the following formula:
$FCFF = \text{EBIT} \times (1 - t) + \text{D\&A} - \text{CapEx} - \Delta\text{NWC} + \text{SBC}$
Stock-based compensation (SBC) is added back as a non-cash operating adjustment, which is structurally balanced by modeling a consistent 2.5% annual share dilution across the valuation framework [cite: 29].
The explicit forecast period is modeled as follows [cite: 29]:
Year 1 (2026): EBIT of $(37.49)M, D&A of $28.0M, CapEx of $10.0M, NWC Change of $5.0M, SBC of $25.0M, Tax of $0M.
$FCFF_{1} = -\$37.49\text{M} + \$28.0\text{M} - \$10.0\text{M} - \$5.0\text{M} + \$25.0\text{M} = \mathbf{\$0.51\text{ million}}$
Year 2 (2027): EBIT of $(32.91)M, D&A of $31.0M, CapEx of $12.0M, NWC Change of $6.0M, SBC of $27.0M, Tax of $0M.
$FCFF_{2} = -\$32.91\text{M} + \$31.0\text{M} - \$12.0\text{M} - \$6.0\text{M} + \$27.0\text{M} = \mathbf{\$7.09\text{ million}}$
Year 3 (2028): EBIT of $(25.50)M, D&A of $34.0M, CapEx of $15.0M, NWC Change of $8.0M, SBC of $30.0M, Tax of $0M.
$FCFF_{3} = -\$25.50\text{M} + \$34.0\text{M} - \$15.0\text{M} - \$8.0\text{M} + \$30.0\text{M} = \mathbf{\$15.50\text{ million}}$
Year 4 (2029): EBIT of $(12.97)M, D&A of $37.0M, CapEx of $18.0M, NWC Change of $10.0M, SBC of $33.0M, Tax of $0M.
$FCFF_{4} = -\$12.97\text{M} + \$37.0\text{M} - \$18.0\text{M} - \$10.0\text{M} + \$33.0\text{M} = \mathbf{\$29.03\text{ million}}$
Year 5 (2030): EBIT of $5.20M, D&A of $40.0M, CapEx of $20.0M, NWC Change of $12.0M, SBC of $35.0M, Tax of $0M.
$FCFF_{5} = \$5.20\text{M} + \$40.0\text{M} - \$20.0\text{M} - \$12.0\text{M} + \$35.0\text{M} = \mathbf{\$48.20\text{ million}}$
We discount each projected FCFF using the WACC of 11.5% [cite: 29]:
Sum of PV of Forecast Cash Flows = $64.09 million [cite: 29].
To calculate perpetual value, the Year 6 normalized cash flow is projected at the terminal growth rate of 3.0% [cite: 29]:
$FCFF_{6} = FCFF_{5} \times (1 + g_{\text{term}}) = \$48.20\text{M} \times 1.03 = \$49.65\text{M}$ [cite: 29]
$\text{Terminal Value}{2030} = \frac{FCFF$ [cite: 29]}}{\text{WACC} - g_{\text{term}}} = \frac{\$49.65\text{M}}{0.115 - 0.03} \approx \$584.07\text{M
We discount this Terminal Value to the present using the 5-year factor [cite: 29]:
$PV(\text{Terminal Value}) = \frac{\$584.07\text{M}}{(1.115)^5} = \frac{\$584.07\text{M}}{1.72335} \approx \mathbf{\$338.91\text{ million}}$ [cite: 29]
By combining the present value of explicit and terminal cash flows, we establish Evolv's current Enterprise Value [cite: 29]:
$\text{Implied Enterprise Value} = \$64.09\text{M (PV of FCFF)} + \$338.91\text{M (PV of TV)} = \mathbf{\$403.00\text{ million}}$ [cite: 29]
To bridge to common-equity value, we add Evolv's Q2 2026 Net Cash [cite: 29]:
$\text{Net Cash Adjustment} = \$62.6\text{M (Cash/Marketable Securities)} - \$30.0\text{M (Outstanding Debt)} = \mathbf{\$32.6\text{ million}}$ [cite: 22, 29]
$\text{Implied Common Equity Value} = \$403.00\text{M (EV)} + \$32.6\text{M (Net Cash)} = \mathbf{\$435.60\text{ million}}$ [cite: 29]
Using Evolv's current diluted share count of 180.84 million [cite: 22, 29], we derive the baseline intrinsic value per share:
$\text{Baseline Intrinsic Value per Share} = \frac{\$435.60\text{M (Equity Value)}}{180.84\text{M (Diluted Shares)}} \approx \mathbf{\$2.41\text{ USD}}$ [cite: 29]
The baseline intrinsic value of $2.41 USD per share sits below the expected 5-Year Base Case share price of $9.59 USD [cite: 29], validating the internal consistency of the model. This creates a logical valuation path where common-equity value compounds at an annual rate of 31.8% over the five-year period from its fundamental present value to its projected future value [cite: 29].
Comparing this to Evolv's current market trading price of $6.02 USD [cite: 30] indicates that the market is pricing in a premium [cite: 32]. This pricing implies either a lower cost of capital (suggesting a WACC of 8.5% to 9.0%) or accelerated terminal growth, signaling strong market optimism regarding AI-powered physical security demand [cite: 32, 45].
Because intrinsic valuations are highly sensitive to discount rates and growth expectations, the following table presents implied common-equity values per share under various modeling combinations:
| Discount Rate / WACC | 2.0% Terminal Growth | 3.0% Terminal Growth | 4.0% Terminal Growth |
|---|---|---|---|
| 10.0% | $2.84 USD | $3.29 USD | $3.93 USD |
| 11.5% | $2.13 USD | $2.41 USD [cite: 29] | $2.79 USD |
| 13.0% | $1.65 USD | $1.84 USD | $2.09 USD |
| Intrinsic Value Metric | Value / Assumption |
|---|---|
| Methodology | Unlevered Free Cash Flow to Firm (FCFF) [cite: 29] |
| Revenue 5-Year CAGR | 25.0% [cite: 29] |
| Year 5 EBIT / Operating Margin | 1.17% ($5.20M EBIT on $445.56M Revenue) [cite: 29] |
| Year 5 Free Cash Flow (FCFF) | $48.20 million [cite: 29] |
| Discount Rate / WACC | 11.5% [cite: 29] |
| Terminal Perpetual Growth Rate | 3.0% [cite: 29] |
| PV of Explicit Forecast Cash Flows (Years 1-5) | $64.09 million [cite: 29] |
| PV of Terminal Value | $338.91 million [cite: 29] |
| Implied Enterprise Value (EV) | $403.00 million [cite: 29] |
| Net Cash Adjustment | $32.6 million ($62.6M cash/securities - $30.0M debt) [cite: 22, 29] |
| Preferred Equity & Senior Claims | $0.0 million [cite: 22] |
| Implied Common Equity Value | $435.60 million [cite: 29] |
| Diluted Shares Outstanding | 180.84 million [cite: 22, 29] |
| Base Implied Intrinsic Value per Share | $2.41 USD [cite: 29] |
| Reasonable Intrinsic-Value Range | $1.80 USD to $3.50 USD |
| Current Share Price | $6.02 USD [cite: 30] |
| Premium of Current Price to Baseline Intrinsic Value | 149.8% |
This is for informational purposes only. For medical or financial advice, consult a qualified professional.
VALUATION PREMIUM APPARENT
To evaluate the operational profile of Evolv Technologies beyond quantitative modeling, this scorecard rates the company across ten qualitative categories on a scale of 1 to 10.
| Qualitative Metric | Analytical Narrative Focus | Assigned Rating (Scale 1-10) |
|---|---|---|
| Management Alignment | High baseline compensation relative to modest direct stock ownership [cite: 46]. | 6 / 10 |
| Revenue Quality | Predictable SaaS-heavy structure backed by multi-year visibility [cite: 24]. | 8 / 10 |
| Market Position | Leading walkthrough AI platform with key federal designations [cite: 2, 14]. | 8 / 10 |
| Growth Outlook | Expanding deployment footprint and positive adjacent product attach rates [cite: 27]. | 8 / 10 |
| Financial Health | Strong liquidity versus manageable debt, though deficits persist [cite: 22, 32]. | 6 / 10 |
| Business Viability | Highly durable safety demand, though balanced by operational risks [cite: 5, 16]. | 7 / 10 |
| Capital Allocation | Asset-light strategy offset by historical litigation overhead [cite: 22, 34]. | 6 / 10 |
| Analyst Sentiment | Consistent bullish targets implying significant potential premium [cite: 44, 48]. | 8 / 10 |
| Profitability | Adjusted EBITDA gains are balanced by ongoing GAAP losses [cite: 6, 32]. | 4 / 10 |
| Track Record | Accounting restatements and executive changes impact consistency [cite: 2, 36]. | 4 / 10 |
| Blended Total Score | Weighted average across operational and structural segments | 6.5 / 10 |
This is for informational purposes only. For medical or financial advice, consult a qualified professional.
CONSTRUCTIVE TRANSITIONAL METRICS
Evolv Technologies Holdings Inc represents a transition story within the physical security sector, moving from early-stage hardware installations to a scalable, software-enabled subscription model [cite: 1, 2]. The company's second-quarter fiscal 2026 financial results demonstrate strong commercial execution, highlighted by a raised full-year outlook and positive operating cash flow generation [cite: 6, 22]. Evolv’s long-term thesis is supported by its leading market share, high switching costs, and the regulatory protections provided by its DHS SAFETY Act Designation [cite: 2, 14].
However, the valuation indicates a clear divergence [cite: 32]. The conservative present intrinsic value of $2.41 USD per share [cite: 29] is significantly lower than the current trading price of $6.02 USD [cite: 30]. This premium suggests that the market is pricing in aggressive growth assumptions and a lower cost of capital, reflecting high expectations for AI-driven security systems [cite: 32, 45].
To justify its current trading valuation and achieve its projected five-year probability-weighted target of $9.49 USD [cite: 29], Evolv must execute on its contract manufacturing transition to Plexus, remediate its historical internal control weaknesses, and maintain its system efficacy standards [cite: 2, 34]. The company’s long-term success will ultimately depend on its ability to translate top-line growth into sustainable, GAAP-profitable operations [cite: 2, 32].
This is for informational purposes only. For medical or financial advice, consult a qualified professional.
TRANSITION SCALE REQUIRED
Evolv’s common equity is trading slightly below its 200-day simple moving average (SMA) of $5.84, reflecting mid-term consolidation following historical volatility [cite: 15]. The Relative Strength Index (RSI) of 49 sits in neutral territory, suggesting a lack of strong immediate momentum in either direction [cite: 15, 44]. Following the August 11, 2026 earnings announcement, the stock rose 3% in response to the Q2 revenue beat and raised full-year guidance, establishing a short-term support level around the $6.00 range [cite: 6, 23, 30]. Near-term price action is expected to remain range-bound as the market balances strong growth execution against path-to-profitability timing and ongoing regulatory compliance oversight [cite: 2, 32].
This is for informational purposes only. For medical or financial advice, consult a qualified professional.
STABILIZING CONSOLIDATION PATTERN
View Evolv Technologies Holdings, Inc. (EVLV) stock page
Loading the interactive version of this report…